Summit Financial LLC Buys 6,823 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Summit Financial LLC boosted its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 26.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 32,687 shares of the biopharmaceutical company’s stock after acquiring an additional 6,823 shares during the period. Summit Financial LLC’s holdings in Esperion Therapeutics were worth $73,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Esperion Therapeutics by 71.8% during the 1st quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock valued at $23,655,000 after purchasing an additional 3,688,796 shares during the period. Armistice Capital LLC purchased a new position in shares of Esperion Therapeutics in the fourth quarter valued at about $9,568,000. Jump Financial LLC bought a new position in shares of Esperion Therapeutics in the fourth quarter worth about $77,000. Bellevue Group AG boosted its stake in shares of Esperion Therapeutics by 136.5% in the first quarter. Bellevue Group AG now owns 9,944,064 shares of the biopharmaceutical company’s stock worth $26,650,000 after acquiring an additional 5,739,800 shares during the period. Finally, Spire Wealth Management grew its position in shares of Esperion Therapeutics by 69.2% during the fourth quarter. Spire Wealth Management now owns 17,767 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 7,267 shares in the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research note on Monday, August 12th. Needham & Company LLC cut their target price on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, August 13th. StockNews.com cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday. Finally, Bank of America downgraded shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and dropped their price objective for the company from $2.90 to $2.50 in a report on Thursday, June 20th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, Esperion Therapeutics presently has a consensus rating of “Hold” and an average price target of $8.17.

Esperion Therapeutics Stock Down 0.5 %

Esperion Therapeutics stock opened at $1.82 on Thursday. Esperion Therapeutics, Inc. has a 52-week low of $0.70 and a 52-week high of $3.40. The firm’s fifty day moving average is $2.15 and its 200 day moving average is $2.30. The company has a market cap of $344.82 million, a price-to-earnings ratio of -1.84 and a beta of 1.02.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.10. The business had revenue of $73.83 million for the quarter, compared to analysts’ expectations of $51.90 million. On average, equities research analysts anticipate that Esperion Therapeutics, Inc. will post -0.04 earnings per share for the current fiscal year.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.